Cargando…

Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy

Human epidermal growth factor receptor 2 (HER2) regulates cell mitosis, proliferation, and apoptosis. Trastuzumab is a HER2-targeted monoclonal antibody (mAB), which can prolong the overall survival rate of patients with HER2 overexpression in later periods of gastric cancer and breast cancer. Altho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Fan, Liu, Yanli, Zhou, Xuexiao, Shen, Pei, Xue, Ran, Zhang, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090390/ https://www.ncbi.nlm.nih.gov/pubmed/35506447 http://dx.doi.org/10.1080/10717544.2022.2069883

Ejemplares similares

Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer
por: Dai, Li, et al.
Publicado: (2022)

Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
por: Huang, Haijun, et al.
Publicado: (2023)

Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report
por: Fan, Shanmin, et al.
Publicado: (2023)

Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
por: Zheng, Yue, et al.
Publicado: (2023)

Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review
por: Qi, Xiangjun, et al.
Publicado: (2022)

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study
por: Wei, Yongbao, et al.
Publicado: (2023)

Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report
por: Qu, Fei, et al.
Publicado: (2023)

Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report
por: Wu, Qifeng, et al.
Publicado: (2022)

Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin
por: Lacouture, Mario E, et al.
Publicado: (2022)

Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”
por: Ingen-Housz-Oro, Saskia, et al.
Publicado: (2022)

Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY(®)) Antibody–Drug Conjugate in Sprague Dawley Rats
por: Yip, Victor, et al.
Publicado: (2021)

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment
por: Zhao, Baiteng, et al.
Publicado: (2016)

Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin
por: Li, Dongwei, et al.
Publicado: (2019)

Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
por: Suri, Ajit, et al.
Publicado: (2018)

Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023)

Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma
por: Van Renterghem, Britt, et al.
Publicado: (2022)

SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
por: Lyon, Robert P., et al.
Publicado: (2023)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study
por: Suri, Ajit, et al.
Publicado: (2019)

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
por: Lobastova, Liudmila, et al.
Publicado: (2021)

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
por: Fu, Zhiwen, et al.
Publicado: (2022)

Brentuximab Vedotin
Publicado: (2012)

Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer
por: Manzano, Aranzazu, et al.
Publicado: (2020)

Antibody–drug conjugates as novel anti-cancer chemotherapeutics
por: Peters, Christina, et al.
Publicado: (2015)

Site-specific antibody drug conjugates for cancer therapy
por: Panowski, Siler, et al.
Publicado: (2013)

Potential of antibody–drug conjugates (ADCs) for cancer therapy
por: Marei, Hany E., et al.
Publicado: (2022)

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
por: Song, Chi Hun, et al.
Publicado: (2023)

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
por: Shim, Hyunbo
Publicado: (2020)

Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020)

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology
por: Esnault, Clara, et al.
Publicado: (2022)

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy
por: Johan, Audrey Nathania, et al.
Publicado: (2022)

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
por: Wu, Mo, et al.
Publicado: (2022)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Microtubule inhibitor-based antibody–drug conjugates for cancer therapy
por: Klute, Kelsey, et al.
Publicado: (2014)

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
por: Dan, Nirnoy, et al.
Publicado: (2018)

Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
por: Chen, Hao, et al.
Publicado: (2017)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
por: Aggarwal, Devesh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6i055k0uubeitgi906tvovk5qu